Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP)
28.00
+4.90 (21.21%)
NASDAQ · Last Trade: May 17th, 1:46 AM EDT
Detailed Quote
Previous Close
23.10
Open
25.17
Bid
27.45
Ask
27.90
Day's Range
25.00 - 30.20
52 Week Range
6.760 - 672.00
Volume
2,537,795
Market Cap
205.09M
PE Ratio (TTM)
-0.1441
EPS (TTM)
-194.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
701,665
Chart
About Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP)
Tonix Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and other serious medical conditions. The company is dedicated to advancing its pipeline of product candidates, which include treatments for conditions such as migraines, post-traumatic stress disorder, and various infectious diseases. By leveraging its expertise in drug development and utilizing strategic collaborations, Tonix aims to bring novel treatment options to market that address unmet medical needs and improve patient outcomes. Read More
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
In his role at Celgene Corp, Hand played a strategic role in transactions including the $74 billion acquisition of Celgene by Bristol Myers Squibb and its subsequent integration.
Tonix Pharmaceuticals (NASDAQ: TNXP) has appointed Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations. Hand brings decades of leadership experience across legal, HR, and corporate services, including a pivotal role in Celgene’s $74 billion acquisition by Bristol Myers Squibb and the $13.4 billion divestiture of Otezla® to Amgen. His addition comes as Tonix prepares for a potential launch of TNX-102 SL for fibromyalgia, pending FDA approval.
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully-integrated biopharmaceutical company, announced financial results for the first quarter of 2025 and reaffirmed its focus on the anticipated FDA decision for TNX-102 SL, a non-opioid analgesic for fibromyalgia, with a PDUFA goal date of Aug. 15. If approved, it would mark the first new drug class for fibromyalgia in more than 15 years. Tonix also highlighted progress across its pipeline, including positive Phase 1 data for TNX-1500 in kidney transplant rejection and strong preclinical results for TNX-801, a live-virus vaccine targeting mpox and smallpox. The company ended the quarter with $131.7 million in cash and cash equivalents and reported a net loss of $16.8 million on $2.4 million in product revenue.
Tonix Pharmaceuticals (NASDAQ: TNXP) presented positive data supporting TNX-1700, its lead immuno-oncology candidate, at the American Association for Cancer Research (AACR) 2025 Annual Meeting. Preclinical results showed that a fusion protein version of TFF2 significantly reduced immunosuppressive neutrophils and enhanced anti-tumor immune responses in gastric cancer models, especially when combined with anti-PD1 therapy. Tonix is advancing TNX-1700 under a license from Columbia University as part of its strategy to develop treatments targeting the tumor microenvironment in gastric and colon cancers.
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully-integrated biopharmaceutical company, presented positive preclinical data on its single-dose mpox vaccine candidate, TNX-801, at the World Vaccine Congress Washington 2025. The oral presentation highlighted TNX-801’s efficacy in protecting animals—including immunocompromised subjects—against both mpox and rabbitpox, with durable protection lasting six months. The minimally replicative live-virus vaccine aligns with the World Health Organization’s preferred target profile, offering potential for broad application in current and future mpox outbreaks declared as global health emergencies.
Tonix Pharmaceuticals (NASDAQ: TNXP) announced a research collaboration with Makana Therapeutics to evaluate TNX-1500, its anti-CD40L monoclonal antibody candidate, in preclinical studies alongside Makana’s human-compatible organs and cells. The studies aim to support a future investigational new drug application to the FDA for compassionate use in xenotransplantation. Makana’s genetically engineered pigs, designed without swine leukocyte antigen, have demonstrated improved human compatibility, positioning both companies to advance potential treatments for organ failure through novel transplant solutions.
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company, presented data at the AAPM 2025 Annual Meeting showing that its investigational drug TNX-102 SL significantly reduced fibromyalgia pain in two randomized, placebo-controlled Phase 3 trials. The sublingual cyclobenzaprine treatment, designed to improve non-restorative sleep, demonstrated robust efficacy and tolerability by targeting sleep disturbance—a key feature of fibromyalgia. CEO Seth Lederman noted the unmet needs in fibromyalgia treatment and highlighted TNX-102 SL as a potential first new option in 15 years.
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a robust development pipeline, announced that CEO Seth Lederman, M.D., will present at the 2025 Jones Trading Healthcare and Innovation Conference. The presentation is scheduled for Wednesday, April 9, at 10 a.m. PT in Las Vegas.
Tonix Pharmaceuticals (NASDAQ: TNXP), a biopharmaceutical company advancing innovative therapies, announced the launch of TONIX ONE , a fully integrated digital platform designed to streamline migraine care. Built through partnerships with UpScript Telemedicine, ProModRx, Blink Health, and a leading symptom-tracking app, TONIX ONE connects patients with migraine specialists, facilitates e-prescriptions, and accelerates treatment access. The platform offers educational tools and real-time support to help patients overcome treatment barriers and improve care outcomes.
Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining attention as it advances TNX-102 SL, a non-opioid investigational therapy for fibromyalgia, toward potential FDA approval by Aug. 15, 2025. The drug, designed to treat chronic pain and sleep disturbances without addiction risks, targets widespread pain and fatigue associated with fibromyalgia—an area where existing treatments like Cymbalta and Lyrica have left many patients dissatisfied. With a sublingual bedtime dose and potential applicability to Long COVID-related pain, TNX-102 SL could offer a scalable alternative in a chronic pain drug market projected to top $115 billion by 2031.
CHATHAM, NEW JERSEY / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.
Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.
Tonix Pharmaceuticals (NASDAQ: TNXP), announced that CEO Seth Lederman, M.D., will present a poster at the AAPM 2025 Annual Meeting, PainConnect, in Austin, Texas. The presentation is scheduled for April 5 at 11:45 a.m. CT during the event, which runs from April 3–6. The company develops and markets biopharmaceutical products and is advancing a pipeline of clinical-stage candidates.
Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.
Tonix Pharmaceuticals (NASDAQ: TNXP), a biopharmaceutical company with marketed products and a robust development pipeline, announced that the FDA will not require an Advisory Committee meeting to evaluate its New Drug Application for TNX-102 SL, a potential new treatment for fibromyalgia. If approved, TNX-102 SL would be the first new fibromyalgia therapy in 15 years. The drug, which previously received Fast Track designation, could launch in the fourth quarter of 2025. TNX-102 SL targets central sensitization and aims to address widespread dissatisfaction with current treatments.
Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not require an Advisory Committee meeting for its New Drug Application for TNX-102 SL.
